跳至主要内容
临床试验/NCT00464685
NCT00464685已完成2 期

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

Allergan0 个研究点目标入组 253 人开始时间: 2007年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Allergan
入组人数
253
主要终点
Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye

研究概览

简要总结

This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with laser treatment vs. laser treatment alone in patients with diabetic macular edema.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older with diabetic macular edema
  • Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse)
  • Visual acuity in other eye no worse than 20/200

排除标准

  • Known anticipated need for ocular surgery within next 12 months
  • History of glaucoma or current high eye pressure requiring more than 1 medication
  • Uncontrolled systemic disease
  • Known steroid-responder
  • Use of systemic steroids - Use of Warfarin/Heparin

研究组 & 干预措施

700 µg Dexamethasone Implant and Laser Photocoagulation

Experimental

Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.

干预措施: Dexamethasone (Drug)

700 µg Dexamethasone Implant and Laser Photocoagulation

Experimental

Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.

干预措施: Laser Photocoagulation (Procedure)

Sham Implant and Laser Photocoagulation

Sham Comparator

Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.

干预措施: Sham injection (Drug)

Sham Implant and Laser Photocoagulation

Sham Comparator

Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.

干预措施: Laser Photocoagulation (Procedure)

结局指标

主要结局

Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye

时间窗: Baseline, Month 12

BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.

次要结局

  • Change From Baseline in the Focal Leakage Area in the Study Eye(Baseline, Month 12)
  • Change From Baseline in Central Subfield Retinal Thickness in the Study Eye(Baseline, Month 12)
  • Time to Retreatment in the Study Eye(12 Months)
  • Change From Baseline in BCVA in the Study Eye(Baseline, Month 12)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验

Safety and Efficacy of a New Treatment in... | 临床试验